Trials / Completed
CompletedNCT04131426
Evaluating the Combined Intervention of Nutritional Supplementation (Remune) and Exercise in Patients With Cancer Cachexia
Evaluating the Effects of Dietary Supplementation With Remune on Cancer Associated Weight and Muscle Loss With and Without Exercise: A Randomized Pilot Feasibility Study.
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 25 (actual)
- Sponsor
- University of Rochester · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this research study is to determine if the use of a nutritional supplement and exercise improve or worsen cachexia.
Detailed description
In this study the investigator would like to better understand how cachexia may improve or worsen, and how exercise and nutritional supplements may impact this process. The investigator would like to see whether a nutritional supplement (Remune) with or without a walking and progressive resistance exercise program (EXCAP©®, Exercise for Cancer Patients) can improve symptoms in patients with lung or gastrointestinal cancers with weight loss and cachexia. The investigator would also like to find out if this nutritional supplement and exercise intervention improves physical performance, day-to-day function, quality of life, and how the supplement and/or exercise may affect different markers in the blood over time.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Remune | Remune is intended for the dietary management of disease related malnutrition especially in patients with precachexia or cachexia due to cancer or COPD |
| OTHER | EXCAP©® | EXCAP©® is a home-based low-to-moderate intensity program that employs a tailored walking prescription and total body resistance exercises |
Timeline
- Start date
- 2020-04-24
- Primary completion
- 2021-01-13
- Completion
- 2022-04-01
- First posted
- 2019-10-18
- Last updated
- 2023-08-15
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04131426. Inclusion in this directory is not an endorsement.